Biofrontera Reports Q1 2026: Revenue $10.1M, Gross Margin ~80%, Adjusted EBITDA $(3.6) M
I'm LongbridgeAI, I can summarize articles.Biofrontera reported Q1 2026 revenue of $10.1 million, a 17% increase year-over-year, with gross margins around 80%. The company faced an operating loss of $4.3 million and a net loss of $4.8 million, while adjusted EBITDA improved to $(3.6) million. Cash and cash equivalents stood at $6.3 million. Key highlights include FDA acceptance of a supplemental NDA for Ameluz PDT and positive Phase 3 results for actinic keratoses. A strategic transaction with Biofrontera AG improved gross margins and compliance with Nasdaq minimum bid price was regained.
Biofrontera reported first-quarter 2026 revenue of $10.1 million, a 17% increase year-over-year, and gross margins of approximately 80% for the quarter. The company recorded an operating loss of $4.3 million and a net loss of $4.8 million, while adjusted EBITDA improved to $(3.6) million. Cash used in operations was minimal at $70 thousand, leaving cash and cash equivalents of $6.3 million as of March 31, 2026.
Financial Highlights
- Revenue: $10.1 million for Q1 2026, up ~17% versus Q1 2025 ($8.6 million).
- Gross profit margin: Approximately 80% in Q1 2026 (compared with ~62% in Q1 2025).
- Operating loss: $4.3 million for Q1 2026 (loss from operations).
- Net loss: $4.8 million for Q1 2026, or $(0.41) per share.
- Adjusted EBITDA: $(3.6) million for Q1 2026 (Adjusted EBITDA margin of (35.3)%).
Business Highlights
- FDA progress: FDA completed filing review and accepted the supplemental NDA for Ameluz PDT for superficial basal cell carcinoma with a PDUFA target action date of September 28, 2026.
- Clinical program milestones: Positive, statistically significant top-line Phase 3 results for Ameluz PDT in mild to moderate actinic keratoses on extremities, neck and trunk, meeting the primary endpoint.
- Regulatory-enabling study: Database lock achieved for a Phase 1 pharmacokinetics study required for FDA filing on treatment fields up to 240 cm² on extremities, neck and trunk.
- Acne program progress: Positive Phase 2b results for moderate to severe acne vulgaris showing a 58% reduction in inflammatory lesions with a 3-hour incubation Ameluz PDT protocol versus 37% with vehicle PDT (PPS).
- Corporate and commercial updates: Strategic Transaction with Biofrontera AG implemented a new earnout structure that materially lowered cost of goods and supported expanded gross margins; Nasdaq minimum bid price compliance regained on May 6, 2026.
Original SEC Filing: Biofrontera Inc. [ BFRI ] - 8-K - May. 14, 2026